Research Alert

Newswise — Nonalcoholic steatohepatitis (NASH)-related cirrhosis can lead to serious liver-related outcomes. In a phase 2 trial, lead author Rohit Loomba, MD, University of California San Diego School of Medicine, and collaborators, report semaglutide 2.4 mg once weekly in patients with NASH-related cirrhosis did not improve fibrosis without worsening of NASH. However, the drug did lead to marked improvements in cardiometabolic risk parameters, liver enzymes, serum fibrosis biomarkers and liver fat.

Journal Link: The Lancet Gastroenterology & Hepatology